Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer

Whole exome sequencing reveals genomic landscape of appendiceal adenocarcinoma

Implementing value based care: Lessons from crisis

Atezolizumab, obinutuzumab and venetoclax combination is active and leads to durable remissions in previously untreated DLBCL-RS

Chemotherapy-free combination of ponatinib and blinatumomab results in high rates of CMR and NGS MRD negativity in Ph positive ALL

Efficacy and safety of belantamab mafodotin vs pomalidomide plus dexamethasone in relapsed/refractory multiple myeloma

Belamaf monotherapy induced rapid responses without unexpected toxicity in relapsed or refractory light chain amyloidosis

KEYNOTE-716: Longer follow up supports pembrolizumab use in stage IIB/IIC melanoma

Primary mediastinal B-cell lymphoma: Radiotherapy superfluous post-chemoimmunotherapy

ASCO 2023: Highlights and analysis

Axi-cel improves survival in early r/r large B-cell lymphoma

CDK4/6 inhibitors added to first line show no greater benefit when compared to their use in second line therapy in HR+, HER2- ABC